lobbying_activities: 2599643
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2599643 | 6f8e6655-4c07-4ae0-b642-7c37a4276b5e | Q1 | AMERICAN SOCIETY OF ADDICTION MEDICINE | 401104864 | AMERICAN SOCIETY OF ADDICTION MEDICINE | 2021 | first_quarter | INS | Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384) Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021. Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan Discussion with ONDCP staff regarding drug policy priorities in 2021 Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 90000 | 0 | 0 | 2021-04-18T07:09:07.443000-04:00 |